Showing results (171-180 of 293) with videos related to
Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve AccrualHolly A Massett, Grace Mishkin, Larry Rubinstein, et al.JCO Clinical Cancer Informatics|January 18, 2019
Technology Applications: Use of Digital Health Technology to Enable Drug DevelopmentJoyce F Liu, Jung-Min Lee, Ellie Strock, et al.Scientific Reports|December 10, 2015
REST mediates resolution of HIF-dependent gene expression in prolonged hypoxiaMiguel A S Cavadas, Marion Mesnieres, Bianca Crifo, et al.Platelets|May 17, 2006
Functional interplay between platelet activation and endothelial dysfunction in patients with coronary heart diseaseS D Robinson, S A Harding, P Cummins, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2013
Developing standards for breakthrough therapy designation in oncologySandra J Horning, Daniel A Haber, Wendy K D Selig, et al.The Oncologist|March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA MutationJoseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignanciesShivaani Kummar, Larry Anderson, Kimberly Hill, et al.Oncotarget|February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working GroupLia Gore, S Percy Ivy, Frank M Balis, et al.Cancer|February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation ProgramAlexander Drilon, Anne A Eaton, Katja Schindler, et al.Pageof 30